Navigation Links
Schizophrenia candidate genes affect even healthy individuals
Date:9/27/2007

., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, notes: The genetics of schizophrenia is turning out to be a complicated story involving many so-called risk gene variants that are actually commonly present in the general population, i.e., people who do not have schizophrenia and will never develop this disorder. It is striking that these genes all effect the glutamate system in the brain. Glutamate is the main excitatory chemical messenger used by the cerebral cortex. Thus, this paper highlights a role for glutamate in the development of schizophrenia-like symptoms, attention deficits, and memory problems. This genetic information adds to a growing body of evidence that highlights the potential importance of glutamate systems as a target for new medications for the treatment of schizophrenia.

Dr. Stefanis, explaining the importance of this study, comments that these findings support the notion that even at the general population level, the genetic liability to psychosis may be expressed as minute and undetected to the naked eye alterations in brain information processing capacity and behavior. Dr. Krystal adds, Consistent with a growing body of evidence, this study suggests that there may be subtle cognitive impairments that are present when these common risk gene variants are present in the general population. Clearly, these findings will have an important impact on the future genetic work in this area.


'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Identifying The Risks Of Developing Schizophrenia
2. Sex exploitation connected to Schizophrenia
3. Schizophrenia detected early
4. No explanation on schizophrenia gene
5. Gene glitches connecting pot with Schizophrenia
6. An insight about Schizophrenia
7. Risk Of Schizophrenia due to Gene Variation
8. Factors That Might Increase The Risk Of Schizophrenia
9. Dads Age Found To Affect The Childs Risk for Schizophrenia
10. Famine May Be A Cause For Schizophrenia
11. Schizophrenia Gets A New Diagnostic Tool
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)...erapy given in conjunction with cancer vaccines ma...mproving the effectiveness of this promising type ...hers in the Duke Comprehensive Cancer Center. , ...hat suppress immune function and we speculated tha... in conjunction with vaccines, which work by boost...
(Date:5/15/2008)...y 15 /PRNewswire-FirstCall/ -- Digital Power,Corpo...y announced its,financial results for the first qu...ed revenue of $3,169,000 for the quarter ended,Mar...for the same quarter,last year. An operating loss ...rted, compared to an operating profit of $25,000 f...
(Date:5/15/2008)...PRNewswire/ -- JumpStart Inc., the Northeast Ohio,...the growth of innovative,early-stage businesses an...,$350,000 in CerviLenz(TM), Inc. The Cleveland-bas...Drug Administration cleared medical,device that al...th in,pregnant women, which has been established b...
(Date:5/15/2008)...Clinton Promise Comprehensive Healthcare Plans, Lo...e, Private Funding, KIRKLAND, Wash., May 15 /PRNe...oduce healthcare reform? "Probably," says Cameron ...nced long term care insurance,agencies, LTC Financ...Clinton,s, or perhaps McCain,s -- cover all health...
Breaking Medicine News(10 mins):Health News:Chemotherapy might help cancer vaccines work 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 3Health News:CerviLenz Receives JumpStart Investment 2Health News:CerviLenz Receives JumpStart Investment 3Health News:Don't Wait for the Election to Plan Your Long-Term Healthcare, Insurance Leader Advises 2
...es have shown inhaled corticosteroids can reduce t... patients experience.// However, results from a st...f Washington show otherwise. Researchers studied m...re prescribed inhaled corticosteroids for at least...
...hows an antiparasitic drug appears to help people ...solium.// Researchers speculated treatment with t...ht might help these patients reduce the number of ...d 120 patients with signs of the living parasite i...
...discovery could help give insight into a very dead...n the gene // that codes for the progesterone rece...e PGR had previously been linked to a higher ovari... cancer risk in women who carry it. Researchers us...
...es have shown inhaled corticosteroids can reduce t... patients experience.// However, results from a st...f Washington show otherwise. Researchers studied m...re prescribed inhaled corticosteroids for at least...
Other Medicine News:
(Date:5/15/2008)...- First in human clinical data highlight safety pr...advanced solid tumors -, BRISBANE, Calif., May 15... held biopharmaceutical company developing novel c...ing its lead PARP inhibitor, BSI-201, will,be pres...ology annual,meeting in Chicago., Findings will b...
(Date:5/15/2008)...hase II Data Presented at ASCO Showed Acceptable T...e of Grade 3 and 4 Neuropathy, WOODCLIFF LAKE, N....motherapeutic agent eribulin mesylate (E7389) demo...on of women with locally advanced or metastatic,br...r Phase II clinical,trial. The study also suggests...
(Date:5/15/2008)... - Unprecedented amount of research reflects dep...rs worldwide to develop new treatments for ...y session to highlight impact of Zometa(R), the le...nts with early-stage breast cancer, - Four oral s...ontinuous, inhibitor of mTOR, including first resu...
(Date:5/15/2008)...od pressure reductions demonstrated in Blacks, His...tes and Obese Individuals, PARSIPPANY, N.J., May ... today that data presented at the American Society... Meeting (ASH 2008) in New,Orleans demonstrated th...ine and olmesartan medoxomil) safely and effective...
Breaking Medicine Technology:BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7EAU Technologies Announces New Chairman of the Board and Board Leadership 5753 1EAU Technologies Announces New Chairman of the Board and Board Leadership 5753 2EAU Technologies Announces New Chairman of the Board and Board Leadership 5753 3EAU Technologies Announces New Chairman of the Board and Board Leadership 5753 4Phlo Affiliate Names Director Of Marketing 1720 1Phlo Affiliate Names Director Of Marketing 1720 2Cost Effectiveness Study Supports Use of EUFLEXXA 28TM 29 by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis 792 1Cost Effectiveness Study Supports Use of EUFLEXXA 28TM 29 by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis 792 2Cost Effectiveness Study Supports Use of EUFLEXXA 28TM 29 by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis 792 3Cost Effectiveness Study Supports Use of EUFLEXXA 28TM 29 by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis 792 4Researchers analyze domestic violence deaths 5752 1Researchers analyze domestic violence deaths 5752 2Researchers analyze domestic violence deaths 5752 3
...harmaceuticals Inc.,(TSX: TLN) announced today tha...ial investigating ECO-4601 in advanced cancer,pati... American,Society of Clinical Oncology (ASCO) Annu...se escalation portion of the study, 14,patients (t...lioma), that had completed and not responded to th...
...res favorably with,the activity of mTOR inhibitors...Call/ - AEterna,Zentaris Inc. , a global biopharma...oncology, today announced that its partner,Keryx ...ase 1 and,Phase 2 results for perifosine, an oral ..., for the treatment of patients with,advanced sarc...
Other Medicine Technology:Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 2Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 3AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 2AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 3AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 4
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: